Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, double-blind, placebo-controlled phase II trial that
will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as
adjuvant treatment for 6 months in patients with surgically resected pancreatic
adenocarcinoma.